Skip to content

Press Release

June 2, 2022

Sysmex Inostics & QIAGEN Highlight Cancer Companion Diagnostics Alliance at ASCO 2022

Two poster presentations utilizing Sysmex Inostics technology to be featured

February 22, 2022

Sysmex Inostics Introduces CLIA-Validated Highly Sensitive HNSCC-SEQ Testing Services for Head and Neck Cancer at the 2022 Molecular Medicine Tri-Conference

Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, will introduce HNSCC-SEQ, a highly sensitive Plasma-Safe-SeqS and Next Generation Sequencing (NGS) assay service for head and neck squamous cell carcinomas (HNSCC), at the annual 2022 Molecular Medicine Tri-Conference being held Monday, February 21st through Wednesday, February 23rd in San Diego, California. The assay has a turn-around-time of 7-10 days and is available to researchers and clinicians.

October 20, 2021

New Ultra-Sensitive Leukemia Blood Test Delivered by Sysmex Inostics

Sysmex Inostics has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML). A global leader and pioneer in blood-based, ultra-sensitive molecular testing for oncology, the company’s new test uses a targeted Next Generation Sequencing (NGS) panel.

July 1, 2021

Sysmex Forms Strategic Alliance with QIAGEN to Provide Global Cancer Companion Diagnostics that Uses Ultra-sensitive Liquid Biopsy NGS Technology

Sysmex Inostics is working to strengthen its global relationship with pharmaceutical companies in order to develop companion diagnostics and timely launch them by capitalizing on Plasma-Safe-SeqS technology, a liquid biopsy developed by Sysmex using a next-generation sequencer (NGS) while leveraging QIAGEN’s experience in developing companion diagnostics.